Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Patrick M. Forde, Jonathan Spicer, Shun Lü, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 1973-1985
Open Access | Times Cited: 1680

Showing 1-25 of 1680 citing articles:

Cancer statistics, 2023
Rebecca L. Siegel, Kimberly D. Miller, Nikita Sandeep Wagle, et al.
CA A Cancer Journal for Clinicians (2023) Vol. 73, Iss. 1, pp. 17-48
Open Access | Times Cited: 11926
Cancer statistics, 2024
Rebecca L. Siegel, Angela N. Giaquinto, Ahmedin Jemal
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 1, pp. 12-49
Open Access | Times Cited: 4232
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Heather A. Wakelee, Moïshe Liberman, Terufumi Kato, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 491-503
Closed Access | Times Cited: 552
Clinical implications of T cell exhaustion for cancer immunotherapy
Andrew Chow, Karlo Perica, Christopher A. Klebanoff, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 12, pp. 775-790
Open Access | Times Cited: 492
Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P. Patel, Megan Othus, Yuanbin Chen, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 9, pp. 813-823
Open Access | Times Cited: 481
Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 449
Therapy with oncolytic viruses: progress and challenges
Sophia Z. Shalhout, David M. Miller, Kevin S. Emerick, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 160-177
Closed Access | Times Cited: 280
Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 18, pp. 1672-1684
Open Access | Times Cited: 276
Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
Mariano Provencio, Ernest Nadal, J.L. González-Larriba, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 504-513
Open Access | Times Cited: 261
Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy
Adrienne Luoma, Shengbao Suo, Yifan Wang, et al.
Cell (2022) Vol. 185, Iss. 16, pp. 2918-2935.e29
Open Access | Times Cited: 235
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Neil D. Gross, David M. Miller, Nikhil I. Khushalani, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 17, pp. 1557-1568
Open Access | Times Cited: 206
Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2155-2161
Open Access | Times Cited: 165
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
Shun Lü, Wei Zhang, Lin Wu, et al.
JAMA (2024) Vol. 331, Iss. 3, pp. 201-201
Open Access | Times Cited: 138
Advances and challenges in the treatment of lung cancer
Yuting Li, Bingshuo Yan, Shiming He
Biomedicine & Pharmacotherapy (2023) Vol. 169, pp. 115891-115891
Open Access | Times Cited: 136
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 14, pp. 1265-1276
Closed Access | Times Cited: 133
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial
Tina Cascone, Cheuk Hong Leung, Annikka Weissferdt, et al.
Nature Medicine (2023) Vol. 29, Iss. 3, pp. 593-604
Open Access | Times Cited: 130
Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Suzanne L. Topalian, Patrick M. Forde, Leisha A. Emens, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1551-1566
Open Access | Times Cited: 129
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Antonio Passaro, Maise Al Bakir, Emily G. Hamilton, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1617-1635
Open Access | Times Cited: 127
Perioperative Nivolumab in Resectable Lung Cancer
Tina Cascone, Mark M. Awad, Jonathan Spicer, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1756-1769
Closed Access | Times Cited: 125
Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial
Joe Y. Chang, Steven H. Lin, Wenli Dong, et al.
The Lancet (2023) Vol. 402, Iss. 10405, pp. 871-881
Open Access | Times Cited: 120
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mari Mino‐Kenudson, Kurt A. Schalper, Wendy A. Cooper, et al.
Journal of Thoracic Oncology (2022) Vol. 17, Iss. 12, pp. 1335-1354
Open Access | Times Cited: 113
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Kailin Yang, Ahmed Halima, Timothy A. Chan
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 604-623
Closed Access | Times Cited: 113
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Giannis Mountzios, Jordi Remón, Lizza Hendriks, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 664-677
Closed Access | Times Cited: 106
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Mark Yarchoan, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 294-311
Closed Access | Times Cited: 103
Squamous cell lung cancer: Current landscape and future therapeutic options
Sally C. M. Lau, Yuanwang Pan, Vamsidhar Velcheti, et al.
Cancer Cell (2022) Vol. 40, Iss. 11, pp. 1279-1293
Open Access | Times Cited: 96
Page 1 - Next Page

Scroll to top